Drug Database
CE

cefaclor (Raniclor / Raniclor)

✓ Approved

Ranbaxy Laboratories Limited · Small Molecule · Small Molecule

What is cefaclor?

cefaclor is a small molecule developed by Ranbaxy Laboratories Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesRaniclor, Raniclor
CompanyRanbaxy Laboratories Limited
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ranbaxy Laboratories Limited

Therapeutic Indications

cefaclor is developed for 6 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved
Respiratory, thoracic and mediastinal disordersTonsillar inflammation✓ Approved

+1 more indication available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedInternational journal of medicinal mushrooms2026-10-13

Pleurotus nebrodensis Mushroom (Agaricomycetes) Polysaccharide Chewable Tablets Alleviate Adenine-Induced Chronic Kidney Disease: Efficacy Assessment and Formulation Optimization.

Yu Yunke Y, Zhang Lidan L, Xu Risheng R, Jia Le L et al.

Chronic kidney disease (CKD), a pathological status characterized by progressive structural and functional deterioration, has emerged as a major global health concern, necessitating urgent attention and effective interventions. This study aimed to characterize Pleurotus nebrodensis polysaccharide (PNPS) and develop a novel P. nebrodensis polysaccharide chewable tablet (PNPT). Briefly, the optimal formulation of PNPT was determined as 20% PNPS, 40% maltose, 0.4% magnesium stearate, 0.2% citric acid, and 39.6% mannitol, respectively. In the mouse experiment, PNPT at both 300 and 600 mg/kg/d dosages showed potential therapeutic efficacy by improving renal function, enhancing antioxidant activity, and inhibiting inflammatory responses. The findings suggested that the PNPS could be used as dietary supplements to develop appropriate products for alleviating CKD and its complications.

PMID 42868535
Read full article →
PubMedFrontiers in oral health2026-10-04

Correction: Evaluation of the plaque removal efficacy of chewable toothpaste tablets - a randomized controlled crossover trial.

Srivastava Harshit H, Chhabra Kumar Gaurav KG, S Naganandini N, Chaudhary Pankaj P et al.

[This corrects the article DOI: 10.3389/froh.2026.1893652.].

PMID 42828007
Read full article →
PubMedEuropean heart journal. Cardiovascular pharmacotherapy2026-09-22

Coated or chewable Aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: Rationale and Design of the COATED-AIR Randomized Trial.

Bikdeli Behnood B, Talasaz Azita H AH, Bakhshandeh Hooman H, Hassanvand Mohammad Sadegh MS et al.

Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular diseases (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2x2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 hours of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrollment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric coated vs chewable aspirin 81mg daily, and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs usual care. The hybrid strategy includes 1. an educational flashcard, 2. real-time air quality alerts via cellular text messages, and recommendations to 2a. limit outdoor activity or 2b. to use a KN-95 facemask when outdoors, and 2c. to increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/nonfatal ischemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrollment was completed on 01/28/2026. Clinical follow-up and blinded event adjudications are ongoing. COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.

PMID 42772753
Read full article →
PubMedAAPS PharmSciTech2026-09-22

Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation.

Oliveira Gabriel S GS, Lima Ana Luiza AL, Muñoz Pedro Granados PG, Gross Idejan P IP et al.

Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability, creating a need for flexible and patient-friendly dosage forms. This study aimed to develop pediatric chewable tablets 6-MP using hot-melt extrusion and fused deposition modeling (FDM) 3D printing. Preformulation studies and rheological characterization were performed to support formulation development. The influence of internal architecture on porosity, disintegration, mechanical properties, and chewability was investigated by varying infill density. Among the evaluated architectures, 30% infill provided the best balance between structural integrity, porosity, rapid disintegration, and softening after saliva exposure, ensuring adequate chewability. Tablets exhibited accurate drug content (99.5 ± 2.2%). Beyond their immediate-release behavior, complete drug release was achieved within 15 min, while colloidal nanostructures were spontaneously formed, associating approximately 11% of dissolved 6-MP, suggesting a hybrid release mechanism combining rapid drug availability with nano-mediated modulation. Dynamic light scattering and transmission electron microscopy confirmed these findings. Overall, the developed platform demonstrates the potential of FDM-based structural engineering to produce personalized pediatric medicines and reveals that thermally processed polymeric matrices may function as dynamic drug delivery systems rather than conventional immediate-release dosage forms.

PMID 42768180
Read full article →
PubMedInternational journal of pharmaceutics2026-09-20

One ink for two processes: Exploiting rheology to accelerate 3D-printed chewable tablet manufacturing.

Abdillah Akbar Bambang V E B BVEB, Gao Shuhan S, Isreb Abdullah A, Khoder Mouhamad M et al.

Personalised medicines are increasingly required in paediatric and hospital pharmacy practice, where licensed preparations may not be suitable. Semi-solid extrusion three-dimensional printing (SSE-3DP) enables the production of these patient-specific dosage forms, including chewable tablets. However, its layer-by-layer fabrication may limit manufacturing speed and routine implementation in time-pressured hospital pharmacy workflows. This study manufactured theophylline-loaded chewable gummy tablets via two routes: conventional SSE-3DP and template-based ink deposition (TID), using an identical printer and without pharmaceutical ink reformulation. The ink was printed directly at a low temperature to produce cylindrical 3DP tablets, whereas in TID, the ink was extruded at a higher temperature into customised pyramidal template cavities. Rheological assessment of the ink under two processing conditions showed that temperature-dependent viscosity behaviour underpinned the distinct manufacturing routes. Following process optimisation, TID shortened the deposition time for gummy tablets to 2-6 s/unit, 7-fold faster than 3DP (14-42 s/unit). When pre-and post-processing were included, total batch completion time per unit was halved. TID tablets met pharmacopeial requirements for weight and content uniformity, showing comparability to 3DP. Distinct drug release profiles were observed for both production methods. Gummy tablets from TID remained physicochemically stable for up to 28 days at 5 and 25 °C. However, the differing thermal and post-processing solidification of the two routes may have resulted in distinct drug-release profiles. Overall, this work extends the functionality of the 3D printer and demonstrates a practical strategy for converting the SSE-3DP process into a rapid dispensing workflow for small-batch personalised gummy medicines in hospital pharmacies and point-of-care settings.

PMID 42764085
Read full article →
PubMedInternational journal of pharmaceutical compounding2026-09-17

Formulation and E-Tongue Evaluation of Taste-Masked Chewable Ferrous Ascorbate Tablets Using Design of Experiment.

Rajagopal Kumaravelrajan K, Sekar Satyanarayanan S, Muthusamy Kannan K, William Clement Atlee CA et al.

This study aims to develop and optimize taste-masked chewable iron tablets using Hydroxypropyl beta-cyclodextrin (HPßCD) and E-Tongue technology to improve patient compliance. A 2-level factorial design was employed to evaluate the effects of HPßCD, isomaltose, and Pearlitol® on the formulation. By using design of experiment the effect of each factor individually on the response can be predicted. There are 8 runs in this design the response for each 8 formulations is predicted individually by using design expert software. The composition of the tablet formulation was optimized using full factorial 23design, which is desirable for response surface methodology to optimize complex formulations. The results demonstrated favorable flow properties, with consistent bulk and tapped densities, and excellent mechanical strength, particularly for F8. In-vitro dissolution studies revealed a high cumulative drug release (93.75%) for F8. E-Tongue analysis indicated that F8 exhibited superior taste-masking efficiency, with the lowest bitterness score. The optimised chewable tablet evaluated for bitter score and hardness. According to point prediction mean predicted was found to be 4.1 for bitter score and observed mean was 4 and for hardness the predicted mean was 13kg/density and observed mean was 14 kg/density. Therefore, the optimised formulation F9 was Drug:CD (1:5), Sweetening agent (11.25mg) and Pearlitol (90 mg) Additionally, chewability was influenced by tablet hardness, with F8 showing the highest chewability difficulty index. The optimized formulation (F8) provides a balanced combination of taste masking, drug release, and mechanical strength, enhancing patient adherence.

PMID 42752429
Read full article →

+2774 more articles available with a free account

Sign up free to view all articles →

Ask about cefaclor